Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, schizophrenia, diabetes, ADHD and chronic migraine.

Latest News

Nov 20, 2014

Heptares Orphan Disease Programme Awarded Grant From The UK Biomedical Catalyst

Nov 17, 2014

Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch


Nov 19-21, 2014
Therapeutic Area Partnerships
Boston, MA, USA
Presenting: Dan Grau

Dec 4, 2014
Society of Medicines Research Meeting: Recent Disclosures of Clinical Candidates
London, UK
Presenting: Giles Brown

© 2012-2014 Heptares Therapeutics